
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-01-08-2014
- Volume 10
- Issue 1
Pall Corporation to Acquire ATMI's LifeSciences Business for $185 million
Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI's LifeSciences business unit for $185 million.
Pall Corporation, a solutions provider in filtration, separation and purification, has signed a definitive agreement with ATMI to acquire ATMI’s LifeSciences business unit for $185 million. ATMI LifeSciences specializes in single-use bioprocess systems and consumables for the bio/pharmaceutical industry. According to the
Pall announced that for the balance of fiscal 2014, the company expects the acquisition to add $20 $30 million in revenue, be $0.05–$0.08 dilutive to EPS on a GAAP basis and almost breakeven on a cash EPS basis. Pall reaffirms its total overall fiscal 2014 guidance for pro forma EPS to be $3.30–$3.50.
Source:
Articles in this issue
almost 12 years ago
New Dynamics in Drug Pricing and Prescribingalmost 12 years ago
Climate Change Drives New Opportunities in Outsourcingalmost 12 years ago
Jimmy Carter and Pfizer Mark 15-Year Effort To Help End Blinding Trachomaalmost 12 years ago
BMS Grants Support Mental Health Needs of US Military Veteransalmost 12 years ago
Cambrex Completes FDA Inspectionalmost 12 years ago
Metrics Appoints New Vice-Presidentalmost 12 years ago
Bridgepoint Development Capital Acquires Quotient Clinicalalmost 12 years ago
GDUFA Off to Good Start, But Storm Clouds on the HorizonNewsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.





